PMID- 23919423
OWN - NLM
STAT- MEDLINE
DCOM- 20140425
LR  - 20221207
IS  - 1521-0499 (Electronic)
IS  - 0190-2148 (Linking)
VI  - 39
IP  - 8
DP  - 2013 Oct
TI  - Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung 
      adenocarcinoma patients.
PG  - 328-35
LID - 10.3109/01902148.2013.819535 [doi]
AB  - INTRODUCTION: Mutation analysis of cancer driver genes is helpful for determining 
      an optimal treatment strategy. We evaluated mutations in four driver genes, 
      namely epidermal growth factor receptor (EGFR), Kirsten ras oncogene (KRAS), 
      c-MET, and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma 
      kinase (EML4-ALK), in Chinese lung adenocarcinoma patients from Hunan Province. 
      METHODS: We enrolled 110 lung adenocarcinoma patients in a single institution. 
      EGFR and KRAS mutations were examined by direct sequencing, the EML4-ALK fusion 
      gene was analyzed by fluorescence in situ hybridization, and c-MET amplification 
      and c-Met protein expression were detected by quantitative PCR and 
      immunohistochemistry, respectively. RESULTS: EGFR and KRAS mutations were 
      observed in 52.7% (58/110) and 3.6% (4/106) of patients, respectively. c-MET 
      amplification was detected in 5.5% (6/110) of patients. In addition, 30% (33/110) 
      of the cases expressed c-Met protein, including all of the patients harboring 
      c-MET amplification. Ten percent (11/110) of patients harbored the EML4-ALK 
      fusion gene, and the frequency of ALK rearrangement was higher than that of other 
      cohort analyses involving patients from other regions in China. Almost all of 
      these gene mutations were exclusive except that in two female non-smoking 
      patients, who harbored an EGFR mutation and EML4-ALK rearrangement 
      simultaneously. In total, 70% of patients in the study harbored one of the four 
      gene mutations. CONCLUSIONS: Most Chinese lung adenocarcinoma patients harbor 
      driver gene mutations, among which ALK rearrangements were more common in Hunan 
      patients than in previously reported populations. Future clinical trials should 
      be conducted to determine the safety and efficacy of drug combination targeting 
      different driver mutations.
FAU - Xia, Ning
AU  - Xia N
AD  - Department of Respiratory Medicine, Xiangya Hospital, Central South University , 
      Changsha, P.R. China.
FAU - An, Jian
AU  - An J
FAU - Jiang, Qing-qing
AU  - Jiang QQ
FAU - Li, Min
AU  - Li M
FAU - Tan, Jun
AU  - Tan J
FAU - Hu, Cheng-ping
AU  - Hu CP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130806
PL  - England
TA  - Exp Lung Res
JT  - Experimental lung research
JID - 8004944
RN  - 0 (EML4-ALK fusion protein, human)
RN  - 0 (KRAS protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Proto-Oncogene Proteins)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (MET protein, human)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - EC 3.6.5.2 (ras Proteins)
SB  - IM
MH  - Adenocarcinoma/*genetics/metabolism/therapy
MH  - Adenocarcinoma of Lung
MH  - Adult
MH  - Aged
MH  - Asian People/genetics
MH  - China
MH  - DNA Mutational Analysis
MH  - ErbB Receptors/genetics
MH  - Female
MH  - Gene Amplification
MH  - *Genes, erbB-1
MH  - Genes, ras
MH  - Humans
MH  - Lung Neoplasms/*genetics/metabolism/therapy
MH  - Male
MH  - Middle Aged
MH  - Molecular Targeted Therapy
MH  - *Mutation
MH  - Oncogene Proteins, Fusion/*genetics
MH  - Proto-Oncogene Proteins/*genetics
MH  - Proto-Oncogene Proteins c-met/*genetics/metabolism
MH  - Proto-Oncogene Proteins p21(ras)
MH  - ras Proteins/*genetics
EDAT- 2013/08/08 06:00
MHDA- 2014/04/26 06:00
CRDT- 2013/08/08 06:00
PHST- 2013/08/08 06:00 [entrez]
PHST- 2013/08/08 06:00 [pubmed]
PHST- 2014/04/26 06:00 [medline]
AID - 10.3109/01902148.2013.819535 [doi]
PST - ppublish
SO  - Exp Lung Res. 2013 Oct;39(8):328-35. doi: 10.3109/01902148.2013.819535. Epub 2013 
      Aug 6.